• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Introducing the new anti-influenza drug, baloxavir marboxil

tetano

tetano

Editor, Senior Moderator
Respir Investig. 2019 Nov 29. pii: S2212-5345(19)30209-6. doi: 10.1016/j.resinv.2019.10.005. [Epub ahead of print] [h=1]Introducing the new anti-influenza drug, baloxavir marboxil.[/h]
Fujita J[SUP]1[/SUP].
[h=3]Author information[/h] 1 University of the Ryukyus Hospital, Okinawa, Japan. Electronic address: fujita@med.u-ryukyu.ac.jp.

[h=4]KEYWORDS:[/h] Anti-influenza drugs; Baloxavir marboxil; I38X substitutions; Influenza; Mass media

PMID: 31791907 DOI: 10.1016/j.resinv.2019.10.005
 
You must log in or register to reply here.
Back
Top Bottom